A CB2 Agonist Changed Morphine Place Preference Without Reducing Self-Administration
The experimental cannabinoid CB2 agonist LY2828360 blocked morphine conditioned place preference in rats but did not reduce morphine self-administration under the tested schedules. Those reward-related outcomes were not interchangeable.
Two behavioral questions were tested
Conditioned place preference measures whether animals spend more time in a setting associated with prior drug exposure. Self-administration measures behavior that produces drug delivery. The study assessed both, using male rats and specified doses and training procedures.
The positive place-preference result had a limit
LY2828360 did not itself produce place preference or aversion at the tested dose and blocked the preference associated with morphine. Yet it did not significantly alter acquisition of intravenous morphine self-administration under the fixed-ratio schedules or motivation to obtain morphine under the progressive-ratio procedure.
The pain experiments answered additional questions
The compound also reduced hypersensitivity in neuropathic-pain models and attenuated morphine tolerance in a nerve-injury regimen. Those findings cannot be combined with the place-preference result to claim that opioid taking or addiction was eliminated. The self-administration experiments also used a different pain context from the neuropathy experiments.
Relevance to cannabis requires chemical precision
LY2828360 is a selective experimental receptor agonist, not THC or a cannabis product. Male-only rodent work, limited doses and particular reinforcement schedules constrain translation. The paper supports investigating a cannabinoid-system target while showing why one favorable reward assay cannot replace direct evidence about drug-taking behavior or treatment outcomes in people.
Related analysis: A THC–Oxycodone Pain Signal Came With a Separate Reward Signal in Mice.
Primary research
The cannabinoid CB2 agonist LY2828360 suppresses neuropathic pain behavior and attenuates morphine tolerance and conditioned place preference in rats. Neuropharmacology (2025). DOI: 10.1016/j.neuropharm.2024.110257.
